Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Terminated
1(13%)

Phase Distribution

Ph early_phase_1
1
13%
Ph phase_4
5
63%
Ph phase_1
1
13%
Ph phase_2
1
13%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 4Post-market surveillance
5(62.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(3)

Detailed Status

Completed5
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (12.5%)
Phase 11 (12.5%)
Phase 21 (12.5%)
Phase 45 (62.5%)

Trials by Status

terminated113%
withdrawn225%
completed563%

Recent Activity

Clinical Trials (8)

Drug Details

Intervention Type
DRUG
Total Trials
8